RadioMedix and Vect-Horus to develop brain theranostic agent for brain cancer

Huge Two-Day Clean Sweep Auction July 24-25th. Click Here to Bid!

advertisement
Current Location:
>
> This Story

starstarstarstarstar (1)
Log in or Register to rate this News Story
Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Molecular Imaging Homepage

Bracco Imaging to acquire Blue Earth Diagnostics for $450 million Will gain rights over Axumin

First dual PET isotope scans performed on living organism Discussed at SNMMI 2019 Annual Meeting

Siemens showcases works in progress at SNMMI Includes TeamPlay, syngo Virtual Cockpit and a number of AI algorithms

MiE showcases cardiac PET scanner, Ancoris, at SNMMI Provides simultaneous 3D cardiac PET perfusion and CFR

Philips shares insights on PET/CT utilization trends at SNMMI Continued growth in use expected through 2019

Software innovations for patient-specific theranostics and molecular radiotherapy Trends that will impact the future of medicine

GE debuts Discovery IQ Gen 2 PET/CT system at SNMMI Equipped with MotionFree to prevent blurring of images

Rethinking training and education for the future of medicine at SNMMI Discussing innovations and efforts of SNMMI Technologist Section

Theranostics continue to gain momentum Investments ramp up but challenges remain

SNMMI Product Showcase Don't miss these solutions on the exhibit floor

RadioMedix and Vect-Horus are working
to develop a theranostics agent for
GBM of the brain

RadioMedix and Vect-Horus to develop brain theranostic agent for brain cancer

by John R. Fischer , Staff Reporter
Vect-Horus, a producer of vectors for the delivery of therapeutic imaging agents, has teamed up with RadioMedix in the development of theranostic agents for the diagnosis and treatment of Glioblastoma Multiforme (GBM) of the brain.

Signing a letter of intent for their agreement, the two plan to utilize Vect-Horus’ VECTrans technology as the basis for the radio-theranostic agents.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED



“Our plan is to utilize VECTrans technology to initially develop an accurate molecular diagnostic PET/CT probe to precisely map the tumor involvement in the brain. This will significantly improve precision of the surgical resection of the tumor,” said Dr. Ebrahim Delpassand, CEO of RadioMedix, in a statement. “The treatment will then be followed by targeted alpha-emitter or beta-emitter radionuclide therapy using the same technology to eradicate any residual malignant cells at the molecular level.”

A theranostic agent targets the low-density Lipoprotein receptor (LDLR) that the cancer cells of glioblastoma express, an action which improves the blood-brain barrier permeability of the drug and selectively delivers the isotope payload to GBM cancer cells.

The use of these agents is supported by findings of PET imaging and biodistribution studies in human glioblastoma xenograft and orthotopic models, which have detected a significant amount of the agent within tumors when delivered.

The agreement combines the expertise of RadioMedix in developing and conducting preclinical evaluations and clinical trials with radiopharmaceuticals, with the Vect-Horus’ VECTrans technology, which is designed to target tumors.

“We look forward to very compelling outcomes from our co-development project, as we seek to create new technologies for the benefit of cancer patients, by giving doctors and hospitals more imaging and treatment options,” said Dr. Jamal Temsamani, Director of Drug Development of Vect-Horus, in a statement.

Vect-Horus declined to comment.

Molecular Imaging Homepage


You Must Be Logged In To Post A Comment